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ImagingWe report a series of novel metanilamide-based derivatives 3a–q bearing the 2-mercapto-4-oxo-4H-
quinazolin-3-yl moiety as tail. All compounds were synthesized by means of straightforward condensa-
tion procedures and were investigated in vitro for their inhibition potency against the human (h) carbonic
anhydrase (CA; EC 4.2.1.1.1) isoforms I, II, IX and XII. Among all compounds tested the 6-iodo 3g and the
7-fluoro 3i derivatives were the most potent inhibitors against the tumor associated CA IX and XII isoform
(KIs 1.5 and 2.7 nM respectively for the hCA IX and KIs 0.57 and 1.9 nM respectively for the hCA XII).
The kinetic data reported here strongly support compounds of this type for their future development as
radiotracers in tumor pathologies which are strictly dependent on the enzymatic activity of the hCA IX
and XII isoforms.
 2017 Elsevier Ltd. All rights reserved.1. Introduction Several classes of compound moieties have been investigatedThe carbonic anhydrase (CAs, EC 4.2.1.1) IX is a validated phar-
macological target for the treatment of hypoxic tumors.1 To date
the hCA IX monoclonal chimeric antibody Girentuximab
(Rencarex) and its iodo radiolabeled derivative (Redectane) are
currently marketed for the treatment and diagnosis of renal cell
carcinomas (RCCs) respectively. Among the small molecule drugs,
the most advanced product in the pipeline is represented by the
sulfanilamide derivative SLC-0111 (Fig. 1) discovered by our group,
which successfully ended its Phase-I trial program.2
Despite the availability of antibody-based drugs, the develop-
ment of small molecules as hCA IX selective inhibitors, such as
the SLC-0111, still remains an attractive approach for two main
reasons: i) small molecule drugs do not suffer of the heavy draw-
backs usually associated to the antibodies such as immunogenic-
ity,3 long circulation times in the bloodstream,4 and low
penetration into solid tumors;5 ii) production costs of clinical grade
antibodies are quite high when compared to ‘‘classical” chemical
drugs.6with the final intent to identify hCA IX selective and druggable
small molecules. The main contributions include phenols and thio-
phenols,7,8 polyamines,9 cyclic and/or fluorinated tertiary sulfon-
amides,10 dithio/monothiocarbamates and xanthates,11,12 as well
as the coumarins and their thio derivatives.13–18 However, the pri-
mary sulfonamides (ASO2NH2) still represent the main class of CA
inhibitors (CAIs) investigated so far. They strongly coordinate the
enzymatic metal ion (Zn2+ in the humans), which is buried at the
low edge of the conical active site,19 whereas the tail of the molec-
ular scaffold is subjected to derivatizations with various chemical
moieties. Such a strategy, commonly referred as the tail approach,
resulted particularly efficient in the obtainment of isoform selec-
tive CAIs of the sulfonamide (-SO2NH2) type,20 but also coumarin,21
sulfocoumarin22 as well as dithiocarbamate derivatives23 were
obtained. From the molecular viewpoint the isoform selectivity
of small molecules through the tail approach resides in the modu-
lation of the number/type of chemical interactions interceding
between the enzymatic rim of the targeted CA, highly variable,
and the tail end of the inhibitor.19c,20 Thus we considered that
the 2-mercapto-4-oxo-4H-quinazolin-3-yl scaffold is of particular
relevance in this context, since it offers multiple sites for
hydrogen bonding interactions, and the additional substitutions
Fig. 1. Chemical structure of the SLC-0111 carbonic anhydrase IX inhibitor.
Fig. 2. Interaction sites offered by the 2-mercapto-4-oxo-4H-quinazolin-3-yl scaffold.
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enzyme complex (Fig. 2).
Herein, as extension of our recent previous reports24–26 and
with the aim to identify selective hCA IX drug leads, we report a
series of sulfonamide compounds possessing the 3-(2-mercapto-
4-oxo-4H-quinazolin-3-yl)-moiety and we explored their inhibi-
tory effects against the four physiological relevant hCA isoforms
such as the cytosolic and abundantly expressed I, II and the tumor
associated IX and XII.
2. Results and discussion
2.1. Chemistry
All compounds reported here, 3a–q, were obtained by using the
same synthetic strategy developed from our groups for the obtain-
ment of 2-mercapto-4-oxo-4H-quinazolin-3-yl scaffolds substi-
tuted at the 3 position with ethylaminobenzene sulfonamides24
or sulfanilamides.25 Specifically for this work we coupled the com-
mercially available anthranilic acids 1a–q with the freshly synthe-
sized 3-isothiocyanato-benzenesulfonamide 2 in alcohol at reflux
(Scheme 1).Scheme 1. General synthetic scheme forAll new compounds reported here were properly characterized
by means of NMR, MS and elemental analyses.
2.2. Carbonic anhydrase inhibition
All synthesized compounds 3a–q were investigated for their
inhibition potencies against the four physiological relevant hCAs
I, II, IX and XII, by means of the stopped flow CO2 hydrase assay,27
and their data compared to the standard CAI acetazolamide
(AAZ).
Overall the compounds 3a–q reported showed interesting inhi-
bitory activities. A structure-activity-relationship (SAR) is below
reported.
i) The cytosolic and abundantly expressed hCA I was the least
inhibited isoform among those considered in this study with
KI values, reported in Table 1, spanning from 135 to
7650 nM. In general 3a and its halogen substituted deriva-
tives 3b–i showed higher inhibition potencies when com-
pared to the alkyl and alkoxy containing counterparts 3j–q
and in the same order of magnitude of the AAZ (Table 1).
Among the first series, the nature of the halide as well as its
position within the 2-mercapto-4-oxo-4H-quinazolin scaf-
fold strongly affected the hCA I inhibition values. For instance
the 7-chloro derivative3cwas 1.7 and 2.1 times stronger than
its 6- and8-chloro-substituted regioisomers respectively. The
8-bromo derivative 3f was more potent than its 7-bromo
derivative 3e (2.1-fold). Conversely when the fluorine atom
was considered, the 6-substituted regioisomer 3h showed
higher inhibition potency when compared to its 7-fluoro
counterpart3i (KIs of 135and169 nMrespectively). Thebulky
6-iodo-2-mercapto-4-oxo-4H-quinazolin derivative 3g was
the least potent among the halogen containing compounds
in inhibiting the hCA I isoform (KI 387 nM).
As above stated the introduction in 3a of alkyl moieties
resulted detrimental for the inhibition potency. The
6-methyl derivative 3j was the most potent in this series in
inhibiting the hCA I isoform (KI 563 nM), followed by the 8-
methyl regioisomer 3k which resulted 1.3 times less potent.
All remaining compounds showed remarkably higher KI val-
ues which were all in the mM range (Table 1).
ii) In analogy to the hCA I, also the cytosolic CA II isoform was
efficiently inhibited from the unsubstituted 3a (KI 14.6 nM)the obtainment of compounds 3a–q.
Table 1
Inhibition data of human CA isoforms hCA I, II, IX and XII with compounds 3a–q and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO2 hydrase
assay.27
Compound R KI (nM)*
hCAI hCA II hCA IX hCA XII
3a H 189 14.6 76.1 10.5
3b 6-Cl 276 19.8 45.1 12.0
3c 7-Cl 164 0.98 15.4 5.8
3d 8-Cl 348 10.7 9.5 3.5
3e 7-Br 296 1.1 16.8 2.4
3f 8-Br 143 0.82 4.0 2.6
3g 6-I 387 27.6 1.5 0.57
3h 6-F 135 7.0 4.4 3.2
3i 7-F 169 6.6 2.7 1.9
3j 6-Me 563 18.6 58.9 45.2
3k 8-Me 719 65.4 25.2 7.6
3l 6,7-(Me)2 1650 210 34.5 9.8
3m 6-MeO 3200 98.4 13.0 10.5
3n 7-MeO 7650 104 25.0 23.4
3o 8-MeO 965 77.8 15.6 23.9
3p 6,7-(MeO)2 3570 126 19.8 4.7
3q 6,7,8-(MeO)3 4600 76.5 20.1 6.0
AAZ – 250 12.0 25.0 5.7
* Mean from 3 different assays, by a stopped flow technique (errors were in the range of ±5–10% of the reported values).
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0.82 nM). Among the halogen containing series a similar
enzymatic profile to the hCA I is also shown. Thus the 7-
chlorosubstituted 2-mercapto-4-oxo-4H-quinazolin scaffold
3c (KI 0.98 nM) was by far more potent in inhibiting the hCA
II than its 6- and 8-regioisomers (KIs 19.8 and 10.7 nM
respectively), and again the 8-bromo derivative 3f was
slightly more potent when compared to its 7-substituted
regioisomer (KIs 0.82 and 1.1 nM respectively). The bulky
iodo derivative 3g was confirmed as the weaker inhibitor
among the halogen containing compounds and even less
potent when compared to the standard CAI AAZ (Table 1).
In the case of the fluoro substituted derivatives 3h and 3i
it is worth noticing that their inhibition profiles against
the hCA II isoform was opposite when compared to the
hCA I. In fact the 7-fluoroderivative was slightly more potent
(0.9-fold) than its 6-substituted regioisomer. Finally as for
the hCA I, the alkyl containing derivatives showed weak KI
data, with the 6- and 8-methyl substituted compounds 3j
and 3k being the strongest in the series (KIs of 18.6 and
65.4 nM respectively).
iii) An interesting enzymatic profile was shown for the trans-
membrane and tumor associated hCA IX. The unsubstituted
3a was the least potent within all the series reported (KI
76.1 nM) and far less active when compared to the standard
CAI AAZ (KI 25 nM). The introduction of a chloro moiety
within the 2-mercapto-4-oxo-4H-quinazolin scaffold to
afford the regioisomers 3b–d, determined a remarkable
increase of the inhibition potency. As shown in Table 1, the
8-substituted derivative 3d was the most potent among
the series with a KI value of 9.5 nM and thus 4.7 and 1.6
times more effective than 3b and 3c respectively. In analogy
to the cytosolic hCA I and II, also for the IX isoform the
in vitro inhibition profiles of the 7- and 8-bromosubstitutedderivatives 3e and 3f were similar (KIs 16.8 and 4.0 nM
respectively). It is noteworthy that in this case their selectiv-
ity index (KI 3f/KI 3e) for the hCA IX isoform is the highest
reported, including the hCA XII discussed later. The fluoro
containing derivatives 3h and 3i showed low nanomolar
inhibition potencies against the hCA IX and no particular dif-
ferences between the two regioisomers were reported (KIs
4.4 and 2.7 nM respectively). Interestingly the iodo deriva-
tive 3g showed a remarkable inhibition potency (KI
1.5 nM), which makes it as the most potent inhibitor against
the IX isoform among all the compound series here reported.
As for the alkyl and alkoxy substituted derivatives 3j–q, the
6-methyl regioisomer 3j was the least effective in inhibiting
the hCA IX (KI 58.9 nM), followed by its doubling 3l (KI
34.5 nM) and by its 8-substituted derivative 3k which
showed a KI value almost identical to the standard CAI
AAZ (25.2 nM and 25.0 nM respectively). Better results were
obtained when the methoxy moieties were introduced as in
compounds 3m–q. Among the monosubstituted methoxy
derivatives, the 6- and the 8-regioisomers were the most
effective (KIs 13.0 and 15.6 nM respectively), whereas the
7-methoxy 3n was the weakest (25.0 nM). Further introduc-
tion of methoxy moieties to afford the di- or tri-substituted
compounds 3p and 3q didn’t result in any significant effect
on the kinetic data (KI 19.8 and 20.1 nM respectively).
iv) The second tumor associated hCA, the XII isoform, resulted
strongly inhibited from all the compounds reported. The
only exception was represented from the 6-methylsubsti-
tuted derivative 3j which showed a KI value of 45.2 nM
(Table 1). The introduction within 3a (KI 10.5 nM) of the
chloro moiety at 6-, 7- and 8-position to afford 3b–d,
resulted in a progressive increase of the inhibition potency
(KIs 12.0, 5.8 and 3.5 nM). The bromo regioisomers 3e and
3f resulted nearly equal for their ability to inhibit the hCA
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the fluoro derivatives, the 7-substituted isomer 3i showed a
preferential inhibition over its 6-fluoro regioisomer 3h
(KIs 1.9 and 3.2 nM respectively). As for the hCA IX, also
the XII isoform resulted strongly inhibited from the iodo
derivative 3g, which was the strongest among all the
compound series reported (KI 0.57 nM). As above stated,
the 6-methyl compound 3jwas the weakest, among all com-
pounds reported, in inhibiting the hCA XII (KI 45.2 nM). It is
interesting to note that the 8-methyl regioisomer 3k (KI
7.6 nM) and the 6,7-dimethyl derivative 3l (KI 9.8 nM)
resulted 5.9 and 4.6 times respectively more potent against
this isoform. A significant influence of the regioselectivity
on the hCA XII inhibition data was also evident for the
methoxy substituted derivatives 3m–o. In this case the
7- and the 8-methoxy compounds 3n and 3o were 2.2. and
2.3 times respectively less potent when compared to the
6-methoxy isomer 3m (KI 10.5 nM). Finally the multiple
introduction of methoxy groups within the 2-mercapto-4-
oxo-4H-quinazolin-3-yl scaffold, as for 3p and 3q, resulted
beneficial for the inhibition potency against the hCA XII, as
they showed KI values comparable to the standard CAI AAZ
(see Table 1).3. Conclusions
We reported a series of new metanilamides bearing the 2-mer-
capto-4-oxo-4H-quinazolin-3-yl as tails. All compounds were
obtained by means of condensation of the freshly prepared 3-
isothiocyanatobenzene sulfonamide 2with commercially available
anthranilic acids. All compounds were investigated in vitro for
their ability to inhibit the most physiological relevant hCA isoforms
such as the cytosolic hCA I, II and the tumor associated IX and XII
isoforms. In general all halogen containing compounds 3b–i
showed higher inhibition potencies against all the hCA isoforms
considered when compared to the unsubstituted 3a as well as to
the alkyl bearing derivatives 3j–q. The hCA I was the least inhibited
isoform, whereas the hCA II, which is deeply involved in glaucoma,
is effectively inhibited from the 7-chloro 3c, 7- and 8-bromo
derivatives 3e and 3f respectively (KIs 0.98, 1.1 and 0.82 nM). As
for the tumor associated hCA IX isoform, the 6-iodo 3g and the
7-fluoro 3i derivatives resulted the most potent inhibitors among
all compounds tested (KIs 1.5 and 2.7 nM respectively). Such result
is of particular interest, since the presence of fluorine and iodine
makes them attractive leads for their possible development as
radiotracers for diagnostic purposes in hypoxic tumors positively
expressing the hCA IX isoform. In analogy to the hCA IX, also the
XII isoform resulted potently inhibited from 3g and 3i (KIs 0.57
and 1.9 nM respectively). In addition the alkyl poly-substituted
derivatives 3p and 3q resulted also quite effective in inhibiting this
isoform with KIs of 4.7 and 6.0 nM and thus comparable to the
halogen derivatives 3b–i.
We conclude that some of these compounds are of particular
relevance for their future development of new leads with diagnos-tic applications in pathologies expressing the hCAs IX and XII such
as the hypoxic tumors.
4. Experimental protocols
4.1. Chemistry
Anhydrous solvents and all reagents were purchased from
Sigma-Aldrich, Alfa Aesar and TCI. All reactions involving air- or
moisture-sensitive compounds were performed under a nitrogen
atmosphere using dried glassware and syringes techniques to
transfer solutions. Nuclear magnetic resonance (1H NMR, 13C
NMR) spectra were recorded using a Bruker Avance III 400 MHz
spectrometer in DMSO-d6. Chemical shifts are reported in parts
per million (ppm) and the coupling constants (J) are expressed in
Hertz (Hz). Splitting patterns are designated as follows: s, singlet;
d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet;
dd, double of doublets. The assignment of exchangeable protons
was confirmed by the addition of D2O. Analytical thin-layer chro-
matography (TLC) was carried out on Merck silica gel F-254 plates.
Flash chromatography purifications were performed on Merck Sil-
ica gel 60 (230–400 mesh ASTM) as the stationary phase and ethyl
acetate/n-hexane were used as eluents. Melting points (m.p.) were
carried out in open capillary tubes and are uncorrected.
4.1.1. Synthesis of 3-isothiocyanato-benzenesulfonamide (2)28Metanilamide (1.0 eq) was dissolved in a 1.0 M hydrochloric
acid aqueous solution and then treated at r.t. with thiophosgene
(1.0 eq). A precipitate was readily formed and the reaction mixture
was stirred overnight The precipitate formed was collected by fil-
tration, washed with H2O and dried under vacuum to afford the
titled compounds as white solids, which were used without further
purification.
3-Isothiocyanato-benzenesulfonamide 2: 81% yield; silica gel
TLC Rf 0.46 (MeOH/DCM 10% v/v); mp 128 C (lit.28 130 C); dH
(400 MHz, DMSO-d6) 7.48 (2H, s, exchange with D2O, SO2NH2),
7.63 (1H, d, J 8.4, Ar-H), 7.68 (1H, dd, J 8.4, Ar-H), 7.89 (1H, d, J
8.4, Ar-H), 7.92 (1H, s, Ar-H); dC (100 MHz, DMSO-d6) 123.0,
124.2, 129.7, 129.9, 130.1 (AN@C@S), 132.0, 142.0; Elemental anal-
ysis: calc: C 39.24, H 2.82, N 13.07, S 29.93; found: C 39.26, H 2.84,
N 13.09, S 29.91; m/z (ESI positive) 215.00 [M+H]+.
4.1.2. General procedure for the synthesis of 3-(2-mercapto-4-oxo-4H-
quinazolin-3-yl)-benzenesulfonamides 3a–q24,25
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1a–q (1.0 eq) and 2-isothiocyanato-benzenesulfonamide 2
(1.0 eq) were suspended in EtOH and the reaction mixture was
refluxed until starting materials were consumed (TLC monitoring).
Then the mixture was cooled down to r.t. and the precipitate
formed was collected by filtration to give a residue that was puri-
fied by trituration from diethyl ether to afford the desired com-
pounds 3a–q.
Synthesis of 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ben-
zenesulfonamide (3a). The titled compound 3a was obtained
according to the general procedure previously reported using 2-
aminobenzoic acid 1a and 2-isothiocyanato-benzenesulfonamide
2. 90% yield, mp <300 C; dH (400 MHz, DMSO-d6) 7.50 (2H, s,
exchange with D2O, SO2NH2), 7.55 (4H, m), 7.67 (2H, m), 7.93
(1H, d, J 7.2), 8.33 (1H, s), 13.16 (1H, s, exchange with D2O, SH);
dC (100 MHz, DMSO-d6) 119.7, 120.6, 122.3, 122.9, 125.1, 127.3,
129.2, 129.4, 134.1, 134.7, 140.2, 147.5, 160.2, 176.9; m/z (ESI neg-
ative) 332.0 [MH].
Synthesis of 3-(6-chloro-2-mercapto-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3b). The titled compound 3bwas obtained
according to the general procedure previously reported using 2-
amino-5-chlorobenzoic acid 1b and 2-isothiocyanato-benzenesul-
fonamide 2. 88% yield, mp <300 C; dH (400 MHz, DMSO-d6) 7.42
(2H, s, exchange with D2O, SO2NH2), 7.58 (3H, m), 7.94 (2H, m),
8.11 (1H, s), 8.38 (1H, s), 13.17 (1H, s, exchange with D2O, SH);
dC (100 MHz, DMSO-d6) 119.6, 121.1, 125.2, 126.3, 127.2, 128.2,
129.3, 130.4, 133.6, 136.5, 140.4, 140.5, 160.6, 176.9; m/z (ESI neg-
ative) 366.0 [MH].
Synthesis of 3-(7-chloro-2-mercapto-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3c). The titled compound 3c was obtained
according to the general procedure previously reported using 2-
amino-4-chlorobenzoic acid 1c and 2-isothiocyanato-benzenesul-
fonamide 2. 69% yield; mp 191 C; dH (400 MHz, DMSO-d6) 7.43
(2H, s, exchange with D2O, SO2NH2), 7.50 (7H, m), 11.34 (1H, s,
exchange with D2O, SH); dC (100 MHz, DMSO-d6) 119.0, 119.5,
122.8, 123.0, 126.8, 127.3, 132.2, 133.5, 133.6, 138.4, 140.0,
148.8, 160.0, 177.5; m/z (ESI positive) 368.00 [M+H]+.
Synthesis of 3-(8-chloro-2-mercapto-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3d). The titled compound 3d was
obtained according to the general procedure previously reported
using 2-amino-3-chlorobenzoic acid 1d and 2-isothiocyanato-ben-
zenesulfonamide 2. 69% yield, mp <300 C; dH (400 MHz, DMSO-d6)
7.50 (2H, s, exchange with D2O, SO2NH2), 7.62 (3H, m), 7.93 (3H,
m), 8.03 (1H, s), 13.01 (1H, s, exchange with D2O, SH); dC
(100 MHz, DMSO-d6) 119.4, 121.8, 125.7, 126.5, 127.2, 127.5,
130.6, 133.5, 136.5, 137.7, 140.6, 146.0, 160.1, 177.4; m/z (ESI neg-
ative) 366.0 [MH].
Synthesis of 3-(7-bromo-2-mercapto-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3e). The titled compound 3ewas obtained
according to the general procedure previously reported using 2-
amino-4-bromobenzoic acid 1e and 2-isothiocyanato-benzenesul-
fonamide 2. 62% yield, mp <300 C; dH (400 MHz, DMSO-d6) 7.48
(2H, s, exchange with D2O, SO2NH2), 7.56 (4H, m), 7.87 (1H, d, J
7.1), 7.93 (2H, m), 13.16 (1H, s, exchange with D2O, SH); dC
(100 MHz, DMSO-d6) 111.5, 117.3, 124.9, 127.1, 128.6, 129.7,
130.1, 130.9, 135.5, 140.8, 142.6, 143.9, 159.4, 177.1; m/z (ESI neg-
ative) 409.9 [MH].
Synthesis of 3-(8-bromo-2-mercapto-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3f). The titled compound 3f was obtained
according to the general procedure previously reported using 2-
amino-3-bromobenzoic acid 1f and 2-isothiocyanato-benzenesul-
fonamide 2. 62% yield; mp 285 C; dH (400 MHz, DMSO-d6) 7.43
(2H, s, exchange with D2O, SO2NH2), 7.60 (7H, m), 13.17 (1H, s,
exchange with D2O, SH); dC (100 MHz, DMSO-d6) 110.0, 120.1,
122.5, 122.7, 124.2, 127.3, 127.8, 130.8, 132.5, 134.4, 140.4,
149.9, 159.9, 177.4; m/z (ESI positive) 411.9 [M+H]+.Synthesis of 3-(6-iodo-2-mercapto-4-oxoquinazolin-3(4H)-yl)
benzenesulfonamide (3g). The titled compound 3g was obtained
according to the general procedure previously reported using 2-
amino-5-iodobenzoic acid 1g and 2-isothiocyanato-benzenesul-
fonamide 2. 82% yield, mp <300 C; dH (400 MHz, DMSO-d6) 7.19
(2H, m), 7.42 (1H, d, J 7.3), 7.46 (1H, d, J 7.2), 7.51 (1H, m), 7.55
(2H, s, exchange with D2O, SO2NH2), 8.15 (1H, d, J 7.3), 8.32 (1H,
d, J 7.2), 13.25 (1H, s, exchange with D2O, SH); dC (100 MHz,
DMSO-d6) 92.8, 119.6, 122.5, 123.8, 126.2, 128.1, 129.4, 134.1,
137.8, 141.3, 143.6, 147.3, 160.4, 177.2; m/z (ESI negative) 457.9
[MH].
Synthesis of 3-(6-fluoro-2-mercapto-4-oxo-4H-quinazolin-3-
yl)-benzenesulfonamide (3h). The titled compound 3h was
obtained according to the general procedure previously reported
using 2-amino-5-fluorobenzoic acid 1h and 2-isothiocyanato-ben-
zenesulfonamide 2. 53% yield, mp <300 C; dH (400 MHz, DMSO-d6)
7.38 (3H, m), 7.54 (2H, s, exchange with D2O, SO2NH2), 7.96 (2H,
m), 8.17 (1H, s), 8.33 (1H, s), 13.19 (1H, s, exchange with D2O,
SH); dF (376 MHz, DMSO-d6) 116.35 (1F, s); dC (100 MHz,
DMSO-d6) 113.5 (d, 2JC-F 24), 117.9 (d, 3JC-F 8), 119.6 (d, 3JC-F 8),
124.5 (d, 2JC-F 24), 125.3, 129.8, 133.6, 138.2,140.4, 143.5, 159.4
(d, 1JC-F 273), 159.8 (d, 4JC-F 3), 161.5, 177.1; m/z (ESI negative)
350.0 [MH].
Synthesis of 3-(7-fluoro-2-mercapto-4-oxo-4H-quinazolin-3-
yl)-benzenesulfonamide (3i). The titled compound 3iwas obtained
according to the general procedure previously reported using 2-
amino-4-fluorobenzoic acid 1i and 2-isothiocyanato-benzenesul-
fonamide 2. 58% yield, mp <300 C; dH (400 MHz, DMSO-d6) 7.23
(2H, m), 7.55 (2H, s, exchange with D2O, SO2NH2), 7.96–8.01 (4H,
m), 8.27 (1H, s), 13.18 (1H, s, exchange with D2O, SH); dF
(376 MHz, DMSO-d6) 101.78 (1F, s); dC (100 MHz, DMSO-d6)
107.3 (d, 2JC-F 26), 114.7 (d, 2JC-F 13), 116.5, 119.4, 123.1, 125.0,
129.4, 130.3, 133.9, 142.3 (d, 3JC-F 13), 145.5 (d, 2JC-F 26), 159.6
(d, 1JC-F 273), 162.1, 176.7; m/z (ESI negative) 350.0 [MH].
Synthesis of 3-(2-mercapto-6-methyl-4-oxo-4H-quinazolin-3-
yl)-benzenesulfonamide (3j). The titled compound 3jwas obtained
according to the general procedure previously reported using 2-
amino-5-methylbenzoic acid 1j and 2-isothiocyanato-benzenesul-
fonamide 2. 62% yield, mp <300 C; dH (400 MHz, DMSO-d6) 2.44
(3H, s), 7.23 (2H, m), 7.55 (2H, s, exchange with D2O, SO2NH2),
7.87 (3H, m), 7.94 (2H, m), 13.13 (1H, s, exchange with D2O, SH);
dC (100 MHz, DMSO-d6) 22.9, 119.5, 120.7, 122.2, 123.1, 125.0,
129.3, 129.8, 133.5, 134.3, 137.5, 140.4, 144.6, 159.3, 177.1; m/z
(ESI negative) 346.0 [MH].
Synthesis of 3-(2-mercapto-8-methyl-4-oxoquinazolin-3(4H)-
yl)benzenesulfonamide (3k). The titled compound 3k was
obtained according to the general procedure previously reported
using 2-amino-3-methylbenzoic acid 1k and 2-isothiocyanato-
benzenesulfonamide 2. 63% yield, mp <300 C; dH (400 MHz,
DMSO-d6) 2.42 (3H, s), 7.25 (2H, m), 7.55 (2H, s, D2O exchangeable,
SO2NH2), 7.78 (3H, m), 7.97 (2H, m), 13.03 (1H, s, exchange with
D2O, SH); dC (100 MHz, DMSO-d6) 23.0, 118.9, 121.1, 123.4,
125.3, 126.3, 127.8, 129.5, 130.9, 132.3, 133.0, 139.1, 140.7,
159.2, 176.5; m/z (ESI negative) 346.0 [MH].
Synthesis of 3-(2-mercapto-6,7-dimethyl-4-oxoquinazolin-3
(4H)-yl)benzenesulfonamide (3l). The titled compound 3l was
obtained according to the general procedure previously reported
using 2-amino-4,5-dimethylbenzoic acid 1l and 2-isothiocyanato-
benzenesulfonamide 2. 68% yield, mp <300 C; dH (400 MHz,
DMSO-d6) 2.85 (6H, s), 6.84 (1H, s), 7.23 (1H, s), 7.56 (2H, s,
exchange with D2O, SO2NH2), 7.91 (4H, m), 13.17 (1H, s, exchange
with D2O, SH); dC (100 MHz, DMSO-d6) 23.7, 27.5, 118.2, 119.8,
122.5, 123.3, 124.2, 127.5, 128.1, 131.9, 134.2, 138.6, 140.8,
143.4, 159.6, 166.5; m/z (ESI negative) 360.0 [MH].
Synthesis of 3-(2-mercapto-6-methoxy-4-oxoquinazolin-3
(4H)-yl)benzenesulfonamide (3m). The titled compound 3m was
M. Bozdag et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2782–2788 2787obtained according to the general procedure previously reported
using 2-amino-5-methoxybenzoic acid 1m and 2-isothiocyanato-
benzenesulfonamide 2. 71% yield; mp >300 C; dH (400 MHz,
DMSO-d6) 3.87 (3H, s), 7.40 (1H, s), 7.48 (2H, s, exchange with
D2O, SO2NH2), 7.54 (2H, s), 7.59 (1H, m), 7.73 (1H, m), 7.78 (1H,
s), 7.91 (1H, d, J 2.0), 13.12 (1H, s, exchange with D2O, SH); dC
(100 MHz, DMSO-d6) 57.8, 105.0, 118.7, 120.0, 120.2, 123.0,
127.2, 128.3, 131.6, 131.8, 138.7, 140.0;158.8, 160.6, 177.8; m/z
(ESI negative) 362.0 [MH].
Synthesis of 3-(2-mercapto-7-methoxy-4-oxoquinazolin-3
(4H)-yl)benzenesulfonamide (3n). The titled compound 3n was
obtained according to the general procedure previously reported
using 2-amino-4-methoxybenzoic acid 1n and 2-isothiocyanato-
benzenesulfonamide 2. 71% yield; mp 297 C; dH (400 MHz,
DMSO-d6) 3.90 (3H, s), 6.95 (1H, s) 7.20 (1H, t, J 7.2), 7.42 (2H, s,
exchange with D2O, OH), 7.65–7.75 (3H, m), 8.05 (2H, m), 13.10
(1H, s, exchange with D2O, SH); dC (100 MHz, DMSO-d6) 57.8,
106.8, 114.2, 115.3, 120.1, 123.1, 125.8, 130.3, 133.2, 133.3,
140.0, 146.6, 160.0, 163.2, 172.5; m/z (ESI positive) 364.0 [M+H]+.
Synthesis of 3-(2-mercapto-8-methoxy-4-oxoquinazolin-3
(4H)-yl)benzenesulfonamide (3o). The titled compound 3o was
obtained according to the general procedure previously reported
using 2-amino-3-methoxybenzoic acid 1o and 2-isothiocyanato-
benzenesulfonamide 2. 62% yield, mp <300 C; dH (400 MHz,
DMSO-d6) 3.94 (3H, s), 7.00 (2H, m), 7.54 (2H, s, exchange with
D2O, SO2NH2), 7.77 (3H, m), 7.94 (2H, m), 12.54 (1H, s, exchange
with D2O, SH); dC (100 MHz, DMSO-d6) 57.1, 119.2, 119.9, 121.1,
121.7, 122.9, 124.3, 125.7, 127.5, 128.4, 132.2, 139.0, 151.2,
159.7, 176.7; m/z (ESI negative) 362.0 [MH].
Synthesis of 3-(2-mercapto-6,7-dimethoxy-4-oxoquinazolin-3
(4H)-yl)benzenesulfonamide (3p). The titled compound 3p was
obtained according to the general procedure previously reported
using 2-amino-4,5-dimethoxybenzoic acid 1p and 2-isothio-
cyanato-benzenesulfonamide 2. 80% yield, mp <300 C; dH
(400 MHz, DMSO-d6) 3.86 (3H, s), 3.92 (3H, s), 6.85 (1H, s), 7.33
(1H, s), 7.55 (2H, s, exchange with D2O, SO2NH2), 7.97 (4H, m),
13.02 (1H, s, exchange with D2O, SH); dC (100 MHz, DMSO-d6)
56.8, 56.9, 99.0, 108.0, 109.5, 126.2, 127.3, 130.4, 133.6, 136.5,
144.5, 145.9, 147.6, 156.4, 160.2, 175.6; m/z (ESI negative) 392.0
[MH].
Synthesis of 3-(2-mercapto-6,7,8-trimethoxy-4-oxoquinazolin-
3(4H)-yl)benzenesulfonamide (3q). The titled compound 3q was
obtained according to the general procedure previously reported
using 2-amino-3,4,5-trimethoxybenzoic acid 1q and 2-isothio-
cyanato-benzenesulfonamide 2. 75% yield, mp <300 C; dH
(400 MHz, DMSO-d6) 3.91 (3H, s), 3.95 (3H, s), 3.96 (3H, s), 7.25
(1H, s), 7.55 (3H, m, 2H exchange with D2O SO2NH2), 7.73 (2H,
m), 7.90 (1H, d, J 8), 12.36 (1H, s, exchange with D2O, SH); dC
(100 MHz, DMSO-d6) 57.1, 61.8, 62.6, 104.2, 112.5, 126.3, 127.2,
130.0, 130.6, 133.6, 140.6, 140.9, 145.9, 148.6, 151.3, 160.1,
175.9; m/z (ESI negative) 422.0 [MH].
4.2. CA inhibition
An Applied Photophysics stopped-flow instrument has been
used for assaying the CA catalyzed CO2 hydration activity.27 Phenol
red (at a concentration of 0.2 mM) has been used as indicator, work-
ing at the absorbance maximum of 557 nm, with 20 mMHepes (pH
7.5) as buffer, and 20 mM Na2SO4 (for maintaining constant the
ionic strength), following the initial rates of the CA-catalyzed CO2
hydration reaction for a period of 10–100 s. The CO2 concentrations
ranged from 1.7 to 17 mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor at least six
traces of the initial 5–10% of the reaction have been used for deter-
mining the initial velocity. The uncatalyzed rates were determined
in the same manner and subtracted from the total observed rates.Stock solutions of inhibitor (0.1 mM) were prepared in distilled-
deionized water and dilutions up to 0.01 nM were done thereafter
with the assay buffer. Inhibitor and enzyme solutionswere preincu-
bated together for 15 min – 6 h at room temperature prior to assay,
in order to allow for the formation of the E-I complex. Data from
Table 1 were obtained after 15 min incubation of enzyme and inhi-
bitor. The inhibition constants were obtained by non-linear least-
squares methods using PRISM 3 and the Cheng-Prusoff equation,
as reported earlier,29,30 and represent the mean from at least three
different determinations. All CA isoforms were recombinant ones
obtained in-house as reported earlier.30Acknowledgments
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